

Table 1: Quality of evidence of study outcomes (GRADE assessment)

Outcomes	Illustrative comparative risks (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
Buzhong Yiqi Decoction (Human studies)				
Muscle mass (ASMI/RASM)	MD 0.99 higher (0.55 to 1.43 higher)	200 (3 RCTs)	$\oplus \oplus \circ \circ$ LOW ^{a,b}	Random effects; I ² =80%
Muscle strength (grip strength)	MD 2.14 higher (0.04 to 4.25 higher)	200 (3 RCTs)	$\oplus \oplus \circ \circ$ LOW ^{a,b}	Random effects; I ² =50%
Muscle function (gait speed)	MD 0.09 higher (-0.09 to 0.27 higher)	140 (2 RCTs)	$\oplus \circ \circ \circ$ VERY LOW ^{a,b,c}	Random effects; I ² =97%
Buzhong Yiqi Decoction (Animal studies)				
Gastrocnemius muscle mass (g)	MD 0.42 higher (0.25 to 0.60 higher)	64 (3 studies)	$\oplus \oplus \circ \circ$ LOW ^{d,e}	Random effects; I ² =65%
Grip strength (g)	MD 240.01 higher (200.82 to 279.20 higher)	66 (4 studies)	$\oplus \oplus \oplus \circ$ MODERATE ^d	Fixed effects; I ² =0%
Exhaustive swimming time (s)	MD 202.86 higher (128.65 to 277.06 higher)	82 (5 studies)	$\oplus \oplus \circ \circ$ LOW ^{d,b}	Random effects; I ² =66%
Shenqi Paste (Human studies)				
Muscle mass (SMI)	MD 0.47 higher (0.01 to 0.93 higher)	267 (2 RCTs)	$\oplus \oplus \circ \circ$ LOW ^{a,b}	Random effects; I ² =86%
Muscle strength (grip strength)	MD 0.51 higher (-1.12 to 2.15 higher)	267 (2 RCTs)	$\oplus \circ \circ \circ$ VERY LOW ^{a,b,c}	Not significant
Muscle function (FTSST)	MD 0.88 lower (-1.90 to 0.14 lower)	267 (2 RCTs)	$\oplus \oplus \circ \circ$ LOW ^{a,b}	Not significant
Bazhen Decoction (Human studies)				
Muscle mass	MD 0.66 higher (-0.62 to 1.94 higher)	304 (2 RCTs)	$\oplus \circ \circ \circ$ VERY LOW ^{a,b,c}	Random effects; I ² =99%
Muscle strength (grip strength)	MD 2.63 higher (-2.53 to 7.78 higher)	304 (2 RCTs)	$\oplus \circ \circ \circ$ VERY LOW ^{a,b,c}	Random effects; I ² =98%
Muscle function (gait speed)	MD 0.15 higher (-0.11 to 0.42 higher)	304 (2 RCTs)	$\oplus \circ \circ \circ$ VERY LOW ^{a,b,c}	Random effects; I ² =100%
Shenling Baizhu Powder (Human studies)				
Muscle mass (SMI)	MD 0.23 higher (-0.09 to 0.55 higher)	317 (2 RCTs)	$\oplus \oplus \circ \circ$ LOW ^{a,b}	Random effects; I ² =91%
Muscle strength (grip strength)	MD 1.65 higher (0.74 to 2.56 higher)	317 (2 RCTs)	$\oplus \oplus \oplus \circ$ MODERATE ^a	Fixed effects; I ² =16%
Muscle function (gait speed)	MD 0.01 higher (-0.01 to 0.03 higher)	317 (2 RCTs)	$\oplus \oplus \circ \circ$ LOW ^{a,c}	Fixed effects; I ² =48%

GRADE Working Group grades of evidence:

High quality ($\oplus \oplus \oplus \oplus$): Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality ($\oplus \oplus \oplus \circ$): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality ($\oplus \oplus \circ \circ$): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality ($\oplus \circ \circ \circ$): We are very uncertain about the estimate.

Downgrading reasons:

^aRisk of bias: Most studies did not report allocation concealment and blinding methods.

^bInconsistency: Substantial heterogeneity ($I^2 > 50\%$).

^cImprecision: Wide confidence intervals crossing the line of no effect.

^dRisk of bias (animal studies): Assessed using SYRCLE tool; concerns about selection and detection bias.

^eIndirectness: Animal model may not fully translate to human outcomes.

Abbreviations: ASMI, appendicular skeletal muscle index; RASM, relative appendicular skeletal muscle mass; SMI, skeletal muscle mass index; FTSST, five-times sit-to-stand test; MD, mean difference; CI, confidence interval; RCT, randomized controlled trial.